Clear Point Advisors Inc. Exelixis, Inc. Transaction History
Clear Point Advisors Inc.
- $122 Billion
- Q2 2024
A detailed history of Clear Point Advisors Inc. transactions in Exelixis, Inc. stock. As of the latest transaction made, Clear Point Advisors Inc. holds 2,450 shares of EXEL stock, worth $87,710. This represents 0.05% of its overall portfolio holdings.
Number of Shares
2,450
Previous 2,600
5.77%
Holding current value
$87,710
Previous $61.7 Million
10.77%
% of portfolio
0.05%
Previous 0.05%
Shares
2 transactions
Others Institutions Holding EXEL
# of Institutions
465Shares Held
240MCall Options Held
1.87MPut Options Held
1.12M-
Black Rock Inc. New York, NY33.5MShares$1.2 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.7MShares$1.06 Billion0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA27.1MShares$970 Million2.95% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.2MShares$543 Million0.6% of portfolio
-
State Street Corp Boston, MA12.6MShares$451 Million0.01% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $11.5B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...